₹ 807.00
10.40 (1.31%)
N
Natco Pharma
₹ 807.00
Natco Pharma Share Price Today
Natco Pharma (NATCOPHARM) share price is trading at ₹807.00 on the NSE as of November 6, 2026 at 03:52 PM, up by 1.31% from its previous close of ₹796.60. In todays trading session NATCOPHARM reached a high of 821.15 and low of 795.05. The average traded price for today is 810.64. The 50 DMA stands at 811.40 and 200 DMA is at 920.60. Looking at intraday trend, the stock is in Uptrend.
Stock Overview
- Symbol : NATCOPHARM
- Open : ₹799.00
- Previous Close : ₹796.60
- Day's Range : ₹795.05 – ₹821.15
- 52-Week Range : ₹773.60 – ₹1,216.81
- Upcoming Event : Q2 FY 26-27 Results (13th Nov 2026, Friday)
Get 20+ Chart Types, 180+ Indicators, 80+ Drawing Tools & Create Custom Indicators for FREE.
NATCOPHARM Stock Performance
Markets Today
High
821.15
Low
795.05
Open at
799.00
Prev Close
796.60
Volumes
7,12,913
Avg Price
810.64
Lower Circuit
645.60
Upper Circuit
968.40
Last Traded Details
Quantity
17
Time
15:52:33
Price Movement
Historical Performance
3 M High
957.00
3 M Low
773.60
1 Yr High
1,216.81
1 Yr Low
773.60
3 Yr High
1,625.66
3 Yr Low
720.88
5 Yr High
1,625.66
5 Yr Low
497.91
1-Year Performance
NATCOPHARM Pros and Cons
API revenue grows from ₹526 Cr in Q1 FY26 to ₹667 Cr in Q1 FY27, showing steady segment expansion.
Domestic formulations revenue rises from ₹1,070 Cr in Q1 FY26 to ₹1,364 Cr in Q1 FY27, confirming strong local demand.
Share of profit from associates jumps from ₹11 Cr in Q3 FY26 to ₹843 Cr in Q1 FY27, boosting consolidated earnings.
Total expenses fall from ₹7,579 Cr in Q1 FY26 to ₹5,487 Cr in Q1 FY27, reflecting disciplined cost control.
Crop health sciences revenue recovers from ₹285 Cr in Q3 FY26 to ₹408 Cr in Q1 FY27, indicating seasonal strength.
Consolidated revenue drops from ₹13,906 Cr in Q1 FY26 to ₹7,944 Cr in Q1 FY27, highlighting top-line contraction.
International formulations revenue falls from ₹11,265 Cr in Q1 FY26 to ₹4,771 Cr in Q1 FY27, pointing to export headwinds.
Profit after tax declines from ₹4,803 Cr in Q1 FY26 to ₹1,222 Cr in Q1 FY27, showing sustained earnings pressure.
Finance cost rises from ₹32 Cr in Q1 FY26 to ₹130 Cr in Q1 FY27, increasing debt servicing burden.
EBITDA slips from ₹6,327 Cr in Q1 FY26 to ₹2,457 Cr in Q1 FY27, reflecting margin compression.
NATCOPHARM Analyst Rating
Buy
Analysts have suggested that investors can
Buy this Stock
- By Refinitiv from 8 analysts
Buy
37.5%
Hold
25%
Sell
37.5%
Get forecast for Price, ROA & ROE based on analyst ratings.
NATCOPHARM Share Price History
NATCOPHARM Fundamentals
Company Valuation
Market Cap (₹ Cr.)
15,831
PE Ratio
13.60
PB Ratio
1.49
Dividend Yield
0.19%
ROE
14.88%
ROCE
16.26%
Book Value (₹)
535.28
Face Value (₹)
2.00
Analyse NATCOPHARM with 12+ custom fundamentals and financial ratios.
Share Holding Pattern
| Held By | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Oct 2026 |
|---|---|---|---|---|---|
| Promoters | 49.48% | 49.42% | 49.42% | 49.39% | 46.22% |
| Domestic Institutional Investors (DII) | 5.39% | 5.46% | 5.62% | 6.16% | 10.82% |
| Foreign Institutional Investors (FII) | 15.16% | 17.37% | 16.99% | 16.00% | 15.36% |
| Public Investors | 25.38% | 23.34% | 23.41% | 23.85% | 22.78% |
| Government | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Promoters
Domestic Institutional Investors (DII)
Foreign Institutional Investors (FII)
Public Investors
Government
Natco Pharma Return Calculator
Note: Past profits do not guarantee future returns.
NATCOPHARM Investment Returns
Short Term
1 Week
1 Month
3 Months
6 Months
9 Months
Long Term
1 Year
2 Years
3 Years
4 Years
5 Years
- In Short Term
- In Long term
1 Week
1 Month
3 Months
6 Months
9 Months
Create Wealth in Longterm with Weekly and Monthly SIP in Stocks.
NATCOPHARM Technicals
Moving Averages
Technical Indicators
Summary of Technical Indicators for NATCOPHARM
Margin on NATCOPHARM
*Calculated on NSE. Applicable on all exchanges. Margins are subject to change from time to time or may be withdrawn under volatile market conditions. Intraday Orders are square-off automatically at 03:19 pm on NSE / BSE or on hitting 80% of margin utilisation (whichever earlier).
NATCOPHARM Financials Summary
In Crores
NATCOPHARM Financials
Income Statement
In Cr
Balance Sheet
In Cr
Cash Flow
In Cr
Corporate Actions
The above dates are ex-dates.
Check NATCOPHARM latest Company Filings, Investor Presentation & Conference Call details.
NATCOPHARM Revenue Growth
All values are in Crores
Revenue
Profit
Loss
NATCOPHARM Similar Stocks
FAQs on NATCOPHARM
What is the share price of Natco Pharma?
What is the 52W high and 52W low of Natco Pharma?
What is the return on Natco Pharma share?
- Past 1 year: -0.76%
- Past 3 years: 9.42%
- Past 5 years: -6.61%
What is the PE and PB Ratio of Natco Pharma?
What is the EPS of Natco Pharma?
What is the shareholding pattern of Natco Pharma?
- DIIs - 10.82%
- FII - 15.36%
- Promoters - 46.22%
- Public Investors 22.78%
- Goverenment - 0.00%
How to buy Natco Pharma shares online?
How to buy Natco Pharma shares on Dhan?
- Download the Dhan App to Open a Demat Account
- Navigate to the “Money Tab”
- Add money to your account
- Search for Natco Pharma share
- Tap on “Buy”
